These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15971403)

  • 21. Comparison of bioavailability of two brands of rifampicin.
    Bhatt AD; Revankar SN
    J Assoc Physicians India; 1999 Jul; 47(7):752. PubMed ID: 10778615
    [No Abstract]   [Full Text] [Related]  

  • 22. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
    Nyazema NZ; Rabvukwa P; Gumbo J; Ndudzo P; Chitemerere C
    Cent Afr J Med; 1999 Jun; 45(6):141-4. PubMed ID: 10695183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Vora MJ
    Int J Pharm; 2001 Oct; 228(1-2):53-67. PubMed ID: 11576768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: is a change required in the direction of the approach in view of recent findings?
    Singh S
    Int J Tuberc Lung Dis; 2001 Sep; 5(9):880-2. PubMed ID: 11573905
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of bioavailability of two brands of rifampicin.
    Rewari S; Rath R; Gupta U
    J Assoc Physicians India; 1998 Aug; 46(8):751. PubMed ID: 11229300
    [No Abstract]   [Full Text] [Related]  

  • 26. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
    van Crevel R; Alisjahbana B; de Lange WC; Borst F; Danusantoso H; van der Meer JW; Burger D; Nelwan RH
    Int J Tuberc Lung Dis; 2002 Jun; 6(6):497-502. PubMed ID: 12068982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):697-9. PubMed ID: 15971401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):689-94. PubMed ID: 11294011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmaceutical study of suppository formulations for improved in vivo kinetics of rifampicin.
    Taki H; Ogawa K; Nikai T
    Kekkaku; 2008 Jun; 83(6):451-6. PubMed ID: 18634449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on a reverse micelle-lamellar phase transition based depot preparation of rifampicin.
    Uppadhyay AK; Omray LK; Khopade AJ; Jain NK
    Pharmazie; 1997 Dec; 52(12):961-2. PubMed ID: 9442561
    [No Abstract]   [Full Text] [Related]  

  • 32. Determination of rifampicin bioequivalence in a three-drug FDC by WHO and indian protocols: effect of sampling schedule and size.
    Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jan; 9(1):75-80. PubMed ID: 15675554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herbal modulation of drug bioavailability: enhancement of rifampicin levels in plasma by herbal products and a flavonoid glycoside derived from Cuminum cyminum.
    Sachin BS; Sharma SC; Sethi S; Tasduq SA; Tikoo MK; Tikoo AK; Satti NK; Gupta BD; Suri KA; Johri RK; Qazi GN
    Phytother Res; 2007 Feb; 21(2):157-63. PubMed ID: 17128432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.
    McIlleron H; Wash P; Burger A; Folb P; Smith P
    Int J Tuberc Lung Dis; 2002 Apr; 6(4):356-61. PubMed ID: 11936746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality control of anti-tuberculosis FDC formulations in the global market: part II-accelerated stability studies.
    Ashokraj Y; Kohli G; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Nov; 9(11):1266-72. PubMed ID: 16333936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement.
    Fourie PB; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S368-70; discussion S381-7. PubMed ID: 10593720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin.
    Becker C; Dressman JB; Junginger HE; Kopp S; Midha KK; Shah VP; Stavchansky S; Barends DM
    J Pharm Sci; 2009 Jul; 98(7):2252-67. PubMed ID: 19160441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Development and estimation of nanosomal rifampicin].
    Oganesian EA; Bud'ko AP; Stukalov IuV; Liubimov II; Biketov SF; Sveshnikov PG; KheĭfetsL B ; Gel'perina SE
    Antibiot Khimioter; 2005; 50(8-9):15-9. PubMed ID: 17016905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol.
    Panchagnula R; Agrawal S; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 2000 Dec; 4(12):1169-72. PubMed ID: 11144460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2004 Jun; 42(6):562-6. PubMed ID: 15260105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.